Head-To-Head Review: Baird Medical Investment (NASDAQ:BDMD) and Edwards Lifesciences (NYSE:EW)

Baird Medical Investment (NASDAQ:BDMD) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Baird Medical Investment and Edwards Lifesciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1	0	0	0	1.00
Edwards Lifesciences	0	9	15	3	2.78

Edwards Lifesciences has a consensus price target of $96.14, indicating a potential upside of 20.90%. Given Edwards Lifesciences’ stronger consensus rating and higher possible upside, analysts plainly believe Edwards Lifesciences is more favorable than Baird Medical Investment.

Volatility & Risk

Baird Medical Investment has a beta of -1.43, meaning that its stock price is 243% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.

Profitability

This table compares Baird Medical Investment and Edwards Lifesciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
Edwards Lifesciences	17.69%	14.50%	11.21%

Valuation & Earnings

This table compares Baird Medical Investment and Edwards Lifesciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	N/A	N/A	N/A	N/A	N/A
Edwards Lifesciences	$6.07 billion	7.56	$1.07 billion	$1.83	43.45

Edwards Lifesciences has higher revenue and earnings than Baird Medical Investment.

Institutional & Insider Ownership

19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Edwards Lifesciences beats Baird Medical Investment on 10 of the 11 factors compared between the two stocks.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.